Search

• US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices votes unanimously to recommend Shingrix for immunocompromised adults aged 19 and up

  Media

  US CDC and Prevention’s Advisory Committee votes unanimously to recommend Shingrix for immunocompromised adults aged 19 & up

  https://www.gsk.com/en-gb/media/press-releases/votes-unanimously-to-recommend-shingrix-for-immunocompromised-adults-aged-19-and-up/

  First published: 20 October 2021

• 

  GSK announces appointments to Designate Haleon Board

  Media

  GlaxoSmithKline plc (GSK) (LSE/NYSE: GSK) today announced the appointment of six directors to the designate Board of Haleon.

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-appointments-to-designate-haleon-board/

  First published: 15 March 2022

• 

  Relvar® Ellipta® 100/25 mcg gains approval in Japan for use in patients with COPD

  Media

  Relvar is a combination of the inhaled corticosteroid, fluticasone furoate, and the long-acting beta2 agonist, vilanterol ‘VI’.

  https://www.gsk.com/en-gb/media/press-releases/relvar-ellipta-10025-mcg-gains-approval-in-japan-for-use-in-patients-with-copd/

  First published: 02 December 2016

• FULFIL study shows superiority of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in improving lung function and health-related quality of life in COPD patients

  Media

  FULFIL - Lung FUnction and quality of LiFe assessment in COPD with closed trIpLe therapy

  https://www.gsk.com/en-gb/media/press-releases/fulfil-study-shows-superiority-of-closed-triple-combination-therapy/

  First published: 20 June 2016

• GSK expands graduated approach to patents and intellectual property to widen access to medicines in the world’s poorest countries

  Media

  GSK has a deep commitment to improving healthcare by developing innovative new medicines and widening access to them around the world.

  https://www.gsk.com/en-gb/media/press-releases/gsk-expands-graduated-approach-to-patents-and-intellectual-property-to-widen-access-to-medicines-in-the-world-s-poorest-countries/

  First published: 31 March 2016

• ViiV Healthcare announces Juluca (dolutegravir/rilpivirine) maintains HIV viral suppression at 148-weeks

  Media

  SWORD studies demonstrate long-term durable efficacy and tolerability of Juluca for treatment of virologically suppressed adults with HIV

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-juluca-dolutegravirrilpivirine-maintains-hiv-viral-suppression-at-148-weeks/

  First published: 03 April 2019

• Shingrix approved in the US for prevention of shingles in immunocompromised adults

  Media

  Immunocompromised individuals are at greater risk of shingles and associated complications than immunocompetent individuals

  https://www.gsk.com/en-gb/media/press-releases/shingrix-approved-in-the-us-for-prevention-of-shingles-in-immunocompromised-adults/

  First published: 26 July 2021

• Jesduvroq (daprodustat) approved by US FDA for anaemia of chronic kidney disease in adults on dialysis

  Media

  Jesduvroq is the only oral HIF-PHI approved in the US, offering adults on dialysis with anaemia of CKD a new oral treatment option

  https://www.gsk.com/en-gb/media/press-releases/jesduvroq-daprodustat-approved-by-us-fda-for-anaemia-of-chronic-kidney-disease-in-adults-on-dialysis/

  First published: 01 February 2023

• US FDA Advisory Committee votes in support of trials designed to evaluate Jemperli (dostarlimab-gxly) as a potential treatment for mismatch repair-deficient/microsatellite instability-high locally advanced rectal cancer

  Media

  In January 2023, the US FDA granted dostarlimab-gxly Fast Track designation for the treatment of dMMR/MSI-H locally advanced rectal cancer.

  https://www.gsk.com/en-gb/media/press-releases/us-fda-advisory-committee-votes-in-support-of-trials-designed-to-evaluate-jemperli-dostarlimab-gxly-as-a-potential-treatment-for-dmmrmsi-h-locally-advanced-rectal-cancer/

  First published: 09 February 2023

• US FDA grants regular approval for Jemperli for the treatment of patients with recurrent or advanced mismatch repair-deficient endometrial cancer

  Media

  Conversion from accelerated to regular (full) approval based on long-term outcomes from the GARNET phase I trial

  https://www.gsk.com/en-gb/media/press-releases/us-fda-grants-regular-approval-for-jemperli-for-the-treatment-of-patients-with-recurrent-or-advanced-mismatch-repair-deficient-endometrial-cancer/

  First published: 10 February 2023